Patent Basics
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Inter Partes Re-Examination: a Low Cost Alternative to Litigation in The
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP Inter partes Re-examination: a Low Cost Alternative to Litigation in the US and Prosecution Strategies in View of the Historically Low Allowance Rate at the by USPTO Anthony C. Tridico, and Carlos M. Téllez Los Lunes de Patentes, Madrid, 30 November 2009 Disclaimer • These materials are public information and have been prepared solely for educational and entertainment purposes to contribute to the understanding of U.S. intellectual property law. These materials reflect only the personal views of the panelists, are not individualized legal advice, and do not reflect the views of Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. It is understood that each case is fact-specific, and that the appropriate solution in any case will vary. Therefore, these materials may or may not be relevant to any particular situation. Thus, Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., and the panelists cannot be bound either philosophically or as representatives of their various present and future clients to the comments expressed in these materials. The presentation of these materials does not establish any form of attorney-client relationship with Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., and the panelists. While every attempt was made to insure that these materials are accurate, errors or omissions may be contained therein, for which any liability is disclaimed. 22 Outline • Re-exam as a low cost alternative to Litigation in the U.S. • Obviousness and KSR as major factors in rejection of applications • Strategies for dealing with KSR in various types of applications • General prosecution tips – If there is time – tips for avoiding inequitable conduct… 33 Monitoring and Detective Work • Time and money is spent monitoring your competitors. -
Is Software Still Patentable?
Is Software Still Patentable? The last four years have posed significant hurdles to software patents; nevertheless they continue to be filed and allowed. By James J. DeCarlo and George Zalepa | August 20, 2018 | The Recorder Over the past four years, decisions by the Supreme Court and Federal Circuit, as interpreted by the U.S. Patent and Trademark Office, have had a dramatic effect on software-related inventions. These decisions have focused primarily on what comprises patentable subject matter under 35 U.S.C. § 101 and whether a patent’s specification adequately supports the claims. While uncertainty still exists, recent court decisions, coupled with sound prosecution strategies, can be used to bolster a practitioner’s arguments before the USPTO and courts. In Alice v. CLS Bank (2014), the Supreme Court applied the now familiar “two-part test” first laid out in Mayo v. Prometheus (2012). Under this test, a claim is first analyzed to determine if it is “directed to” an abstract idea. If so, the claim is then analyzed to determine whether it recites “significantly more” than the identified abstract idea or just “routine and conventional” elements. This test was (and is) routinely applied to software claims, and the pendulum of patentability for software inventions post-Alice swung firmly towards ineligibility. Nearly all decisions by the Federal Circuit in the immediate aftermath of Alice found claims ineligible. Similarly, the USPTO’s allowance rate in software-related art units plummeted, and many allowed but not yet issued applications were withdrawn by the USPTO. While many cases are representative of this period, the decision in Electric Power Group v. -
Federal Circuit Year in Review
ss TABLE OF CONTENTS Page INTRODUCTION .......................................................................................................................... 1 ACKNOWLEDGEMENT .............................................................................................................. 2 GIBSON DUNN’S FEDERAL CIRCUIT CLERKS ..................................................................... 3 STATISTICAL ANALYSIS .......................................................................................................... 6 INDEX BY ISSUE ....................................................................................................................... 28 CASE SUMMARIES ................................................................................................................... 44 ALPHABETICAL INDEX OF ALL CASES ............................................................................. 133 INTRODUCTION The Federal Circuit’s 2019‒2020 term saw a number of important developments in patent law. The Court issued 130 published opinions. This term included significant panel decisions in patent law jurisprudence with regard to the constitutionality of the PTAB and its jurisdiction and procedures (Arthrex, Inc. v. Smith & Nephew, Inc., 941 F.3d 1320 (Fed. Cir. 2019), Samsung Electronics America, Inc. v. Prisua Engineering Corp., 948 F.3d 1342 (Fed. Cir. 2020), and Nike, Inc. v. Adidas AG, 955 F.3d 45 (Fed. Cir. 2020)), subject matter eligibility (American Axle & Manufacturing, Inc. v. Neapco Holdings LLC, 967 F.3d 1285 (Fed. Cir. -
Confusing Patent Eligibility
CONFUSING PATENT ELIGIBILITY DAVID 0. TAYLOR* INTRODUCTION ................................................. 158 I. CODIFYING PATENT ELIGIBILITY ....................... 164 A. The FirstPatent Statute ........................... 164 B. The Patent Statute Between 1793 and 1952................... 166 C. The Modern Patent Statute ................ ..... 170 D. Lessons About Eligibility Law ................... 174 II. UNRAVELING PATENT ELIGIBILITY. ........ ............. 178 A. Mayo Collaborative Servs. v. Prometheus Labs............ 178 B. Alice Corp. v. CLS Bank Int'l .......... .......... 184 III. UNDERLYING CONFUSION ........................... 186 A. The Requirements of Patentability.................................. 186 B. Claim Breadth............................ 188 1. The Supreme Court's Underlying Concerns............ 189 2. Existing Statutory Requirements Address the Concerns with Claim Breadth .............. 191 3. The Supreme Court Wrongly Rejected Use of Existing Statutory Requirements to Address Claim Breadth ..................................... 197 4. Even if § 101 Was Needed to Exclude Patenting of Natural Laws and Phenomena, A Simple Statutory Interpretation Would Do So .................... 212 C. Claim Abstractness ........................... 221 1. Problems with the Supreme Court's Test................221 2. Existing Statutory Requirements Address Abstractness, Yet the Supreme Court Has Not Even Addressed Them.............................. 223 IV. LACK OF ADMINISTRABILITY ....................... ....... 227 A. Whether a -
Update on Discovery of Patent Prosecution Communications by Jeffrey Thomas, Anne Brody and Pamela Lee
Portfolio Media. Inc. | 111 West 19th Street, 5th Floor | New York, NY 10011 | www.law360.com Phone: +1 646 783 7100 | Fax: +1 646 783 7161 | [email protected] Update On Discovery Of Patent Prosecution Communications By Jeffrey Thomas, Anne Brody and Pamela Lee Law360, New York (June 20, 2017, 5:19 PM EDT) -- In general, communications between an attorney and his client relating to the filing and prosecution of a patent application are privileged. Last year, the Federal Circuit found that such communications between a patent agent and his client are also privileged.[1] But under the joint attorney-client privilege or the common interest doctrine, communications between attorneys and two or more clients may not be privileged in a later dispute between these clients. This article discusses the challenges that courts and companies continue to face in determining whether a party can access these patent prosecution communications in disputes: (1) between two joint owners; (2) between an employer-owner and an employee- inventor; and (3) with respect to a patent agent, in other Circuits and state courts. Jeffrey Thomas Do Joint Owners Share a Joint Attorney-Client Privilege During Patent Prosecution? When a dispute arises between two joint owners, one owner may seek to access the other owner’s communications with the patent attorney relating to the patent prosecution process. In that case, a court would look at a few factors to decide. One factor would be whether the patent prosecution process was handled by only one attorney (e.g., an in-house attorney), or by two attorneys separately representing the two owners. -
Patenting Life in the European Community: the Proposed Directive on the Legal Protection for Biotechnological Inventions
Fordham Intellectual Property, Media and Entertainment Law Journal Volume 4 Volume IV Number 2 Volume IV Book 2 Article 1 1993 Patenting Life in the European Community: The Proposed Directive on the Legal Protection for Biotechnological Inventions Janice McCoy Follow this and additional works at: https://ir.lawnet.fordham.edu/iplj Part of the Entertainment, Arts, and Sports Law Commons, and the Intellectual Property Law Commons Recommended Citation Janice McCoy, Patenting Life in the European Community: The Proposed Directive on the Legal Protection for Biotechnological Inventions, 4 Fordham Intell. Prop. Media & Ent. L.J. 501 (1993). Available at: https://ir.lawnet.fordham.edu/iplj/vol4/iss2/1 This Article is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Intellectual Property, Media and Entertainment Law Journal by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more information, please contact [email protected]. ARTICLES Patenting Life in the European Community: The Proposed Directive on the Legal Protection for Biotechnological Inventions Janice McCoy' INTRODUCTION Technology has once again overtaken the law. Ever since the United States Supreme Court concluded in 1980 that anything un- der the sun that was made by man could be patented,' and especial- ly since the United States Patent and Trademark Office ("USPTO") announced in 1987 that it considered nonnaturally occurring non- human animals to be patentable subject matter,2 legislative bodies in both the United States and the European Economic Community ("EEC") have been debating to what extent living matter should be patentable. -
Patent Law: a Handbook for Congress
Patent Law: A Handbook for Congress September 16, 2020 Congressional Research Service https://crsreports.congress.gov R46525 SUMMARY R46525 Patent Law: A Handbook for Congress September 16, 2020 A patent gives its owner the exclusive right to make, use, import, sell, or offer for sale the invention covered by the patent. The patent system has long been viewed as important to Kevin T. Richards encouraging American innovation by providing an incentive for inventors to create. Without a Legislative Attorney patent system, the reasoning goes, there would be little incentive for invention because anyone could freely copy the inventor’s innovation. Congressional action in recent years has underscored the importance of the patent system, including a major revision to the patent laws in 2011 in the form of the Leahy-Smith America Invents Act. Congress has also demonstrated an interest in patents and pharmaceutical pricing; the types of inventions that may be patented (also referred to as “patentable subject matter”); and the potential impact of patents on a vaccine for COVID-19. As patent law continues to be an area of congressional interest, this report provides background and descriptions of several key patent law doctrines. The report first describes the various parts of a patent, including the specification (which describes the invention) and the claims (which set out the legal boundaries of the patent owner’s exclusive rights). Next, the report provides detail on the basic doctrines governing patentability, enforcement, and patent validity. For patentability, the report details the various requirements that must be met before a patent is allowed to issue. -
Attorney-Client Privilege and the Patent Prosecution Process in the Post-Spalding World
Washington University Law Review Volume 81 Issue 1 2003 Attorney-Client Privilege and the Patent Prosecution Process in the Post-Spalding World Jonathan G. Musch Washington University School of Law Follow this and additional works at: https://openscholarship.wustl.edu/law_lawreview Part of the Evidence Commons, Intellectual Property Law Commons, Legal Ethics and Professional Responsibility Commons, and the Legal Profession Commons Recommended Citation Jonathan G. Musch, Attorney-Client Privilege and the Patent Prosecution Process in the Post-Spalding World, 81 WASH. U. L. Q. 175 (2003). Available at: https://openscholarship.wustl.edu/law_lawreview/vol81/iss1/5 This Note is brought to you for free and open access by the Law School at Washington University Open Scholarship. It has been accepted for inclusion in Washington University Law Review by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. ATTORNEY-CLIENT PRIVILEGE AND THE PATENT PROSECUTION PROCESS IN THE POST- SPALDING WORLD I. INTRODUCTION One of the oldest traditions of the Anglo-American judicial system is the concept of attorney-client privilege.1 This privilege and its much younger sibling, the work-product doctrine,2 limit the discoverability of private communications between attorney and client.3 Private communications4 between a patent attorney and a client, however, have not always enjoyed this protection.5 Due to a misconception of the role of a patent attorney within the patent prosecution process, courts denied attorney-client privilege first to all patent prosecution documents, and later to documents containing technical information. This effectively denied the privilege to most documents generated during a prosecution.6 More recently, courts afforded certain documents containing technical information protection, but under a patchwork of different standards.7 Frequently, a disagreement existed between different district courts within a circuit,8 as well as among different circuits.9 The exponential technology 1. -
Horizon Book of Authorities
PATENTED MEDICINE PRICES REVIEW BOARD IN THE MATTER OF THE PATENT ACT R.S.C. 1985, C. P-4, AS AMENDED AND IN THE MATTER OF HORIZON PHARMA PLC (THE “RESPONDENT”) AND THE MEDICINE CYSTEAMINE BITARTRATE SOLD BY THE RESPONDENT UNDER THE TRADE NAME PROCYSBI® BOOK OF AUTHORITIES OF THE RESPONDENT (MOTION TO BIFURCATE, STRIKE EVIDENCE AND FOR THE INSPECTION AND PRODUCTION OF DOCUMENTS) Torys LLP 79 Wellington St. W., Suite 3000 Toronto ON M5K 1N2 Fax: 416.865.7380 Sheila R. Block Tel: 416.865.7319 [email protected] Andrew M. Shaughnessy Tel: 416.865.8171 [email protected] Rachael Saab Tel: 416.865.7676 [email protected] Stacey Reisman Tel: 416.865.7537 [email protected] Counsel to Respondent, Horizon Pharma PLC INDEX 1. Board Decision – Alexion Pharmaceuticals Inc. and the Medicine “Soliris” (September 20, 2017) 2. Alexion Pharmaceuticals Inc. v. Canada (Attorney General), 2019 FC 734 3. Celgene Corp. v. Canada (Attorney General), 2011 SCC 1 4. Board Decision – Alexion Pharmaceuticals Inc. and the Medicine “Soliris” (March 29, 2016) 5. Mayne Pharma (Canada) Inc. v. Aventis Pharma Inc., 2005 FCA 50 6. P.S. Partsource Inc. v. Canadian Tire Corp., 2001 FCA 8 7. Harrop (Litigation Guardian of) v. Harrop, 2010 ONCA 390 8. Merck & Co v. Canada (Minister of Health), 2003 FC 1511 9. Vancouver Airport Authority v. Commissioner of Competition, 2018 FCA 24 10. Merck & Co, Inc. v. Canada (Minister of Health), 2003 FC 1242 11. H-D Michigan Inc. v. Berrada, 2007 FC 995 12. Roger T. Hughes, Arthur Renaud & Trent Horne, Canadian Federal Courts Practice 2019 (Toronto: LexisNexis Canada Inc., 2019) 13. -
Compulsory Patent Licensing: Is It a Viable Solution in the United States Carol M
Michigan Telecommunications and Technology Law Review Volume 13 | Issue 2 2007 Compulsory Patent Licensing: Is It a Viable Solution in the United States Carol M. Nielsen Michael R. Samardzija University of Texas M.D. Anderson Cancer Center Follow this and additional works at: http://repository.law.umich.edu/mttlr Part of the Administrative Law Commons, and the Intellectual Property Law Commons Recommended Citation Carol M. Nielsen & Michael R. Samardzija, Compulsory Patent Licensing: Is It a Viable Solution in the United States, 13 Mich. Telecomm. & Tech. L. Rev. 509 (2007). Available at: http://repository.law.umich.edu/mttlr/vol13/iss2/9 This Symposium Article is brought to you for free and open access by the Journals at University of Michigan Law School Scholarship Repository. It has been accepted for inclusion in Michigan Telecommunications and Technology Law Review by an authorized editor of University of Michigan Law School Scholarship Repository. For more information, please contact [email protected]. COMPULSORY PATENT LICENSING: IS IT A VIABLE SOLUTION IN THE UNITED STATES? Carol M. Nielsen* Michael R. Samardzija** Cite as: Carol M. Nielsen and Michael R. Samardzija, Compulsory Patent Licensing: Is It a Viable Solution in the United States?, 13 MICH. TELECOMM. TECH. L. REV. 509 (2007), available at http://www.mttlr.org/volthirteen/nielsen&samardzija.pdf As technology continues to advance at a rapid pace, so do the number of patents that cover every aspect of making, using, and selling these innovations. In 1996, to compound the rapid change of technology, the U.S. Supreme Court affirmed that business methods are also patentable. -
Patents and the Public Domain: Improving Patent Quality Upon Reexamination
Patents and the Public Domain: Improving Patent Quality Upon Reexamination Prepared by Policy Intern Raeanne Young [email protected] May 2008 ELECTRONIC FRONTIER FOUNDATION eff.org Table of Contents EXECUTIVE SUMMARY ........................................................................................................................3 PATENTS AND THE PUBLIC DOMAIN .....................................................................................................4 The Problem With Patent Quality ..................................................................................................4 Policy Rationale: Encouraging Innovation .......................................................................................4 PATENT REEXAMINATION ...................................................................................................................6 Ex parte and Inter partes .............................................................................................................6 OVERALL REEXAMINATION TRENDS ......................................................................................................8 Ex Parte Reexamination Filing Data: July , 98 - December 3, 2007 ...............................................8 Inter Partes Reexamination Filing Data: November 29, 999 - December 3, 2007 .............................0 Comparison of Ex Parte and Inter Partes ......................................................................................0 PROMOTING FAIRNESS IN THE PATENT SYSTEM THROUGH REEXAMINATION .............................................2 -
Life Sciences & Biotechnology Legal Bulletin
ISSUE 29 | FEBRUARY 16, 2012 LIFE SCIENCES & BIOTECHNOLOGY LEGAL BULLETIN SCIENCE • TECHNOLOGY ENGINEERING • ENERGY PHARMACEUTICAL CONTENTS IP NEWS IP News USPTO Proposes New Rules of Trial and Appellate Practice Under AIA ...........1 USPTO Proposes New Rules of Trial and Appellate Practice Under AIA Investor News The U.S. Patent and Trademark Office (USPTO) has issued proposed rules of Massachusetts Biotech Adds $6.3 Million practice to implement sections of the America Invents Act (AIA) that provide Targeted to Stem Cell Reagents .........2 for trials before the Patent Trial and Appeal Board and address judicial review of Biopharmaceutical Secures $2.2 Million to Develop Pancreatic Cancer Vaccine ...2 board decisions. Comments are requested by April 9, 2012. Business Climate According to USPTO’s notice, “the proposed rules would provide a consolidated Life Sciences Startups Generate More Capital in 2011, Biotech Job Ads Down set of rules relating to Board trial practice for inter partes review, post-grant Slightly in Q4 ...........................2 review, derivation proceedings, and the transitional program for covered Companion Diagnostics in Personalized business method patents by adding a new part 42 including a new subpart A Medicine Facing Explosive Growth ......3 to title 37 of the Code of Federal Regulations. The proposed rules would also Indian Official Calls for Passage of Biotech Regulatory Legislation and provide a consolidated set of rules to implement the provisions of the Leahy- Increased VC Funding. 3 Smith America Invents Act related to seeking judicial review of Board decisions Legislative and Regulatory Developments by adding a new part 90 to title 37 of the Code of Federal Regulations.” Separate FDA Issues Draft Biosimilars Guidance, rulemakings address proposed rules specific to inter partes review, post-grant Gaps Leave Practitioners Wondering ....4 review, the transitional program for covered business method patents, and Pay-for-Delay Deals and Biologics’ Exclusivity Period Part of President’s derivation proceedings.